DOSE — Rapid Dose Therapeutics Income Statement
0.000.00%
Last trade - 00:00- CA$21.92m
- CA$27.24m
- CA$2.09m
Annual income statement for Rapid Dose Therapeutics, fiscal year end - February 28th, CAD millions except per share, conversion factor applied.
R2021 February 28th | 2022 February 28th | 2023 February 28th | C2024 February 29th | 2025 February 28th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.755 | 1.75 | 0.718 | 1.02 | 2.09 |
| Cost of Revenue | |||||
| Gross Profit | 0.7 | 1.34 | 0.372 | 0.563 | 1.18 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 2.53 | 10.3 | 4.53 | 5.33 | 7.49 |
| Operating Profit | -1.78 | -8.52 | -3.81 | -4.31 | -5.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1.81 | -8.49 | -3.81 | -4.31 | -5.4 |
| Net Income After Taxes | -1.81 | -8.49 | -3.81 | -4.31 | -5.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.81 | -8.49 | -3.81 | -4.31 | -5.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.81 | -8.49 | -3.81 | -4.31 | -5.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.022 | -0.043 | -0.037 | -0.036 | -0.043 |